Tianjin Tianyao Pharmaceuticals Co., Ltd.

SHSE:600488 Stock Report

Market Cap: CN¥4.9b

Tianjin Tianyao Pharmaceuticals Past Earnings Performance

Past criteria checks 4/6

Tianjin Tianyao Pharmaceuticals's earnings have been declining at an average annual rate of -0.9%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 3.9% per year. Tianjin Tianyao Pharmaceuticals's return on equity is 5.4%, and it has net margins of 4.3%.

Key information

-0.9%

Earnings growth rate

-1.1%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate3.9%
Return on equity5.4%
Net Margin4.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

Tianjin Tianyao Pharmaceuticals (SHSE:600488) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Nov 05
Tianjin Tianyao Pharmaceuticals (SHSE:600488) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Recent updates

Tianjin Tianyao Pharmaceuticals (SHSE:600488) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Nov 05
Tianjin Tianyao Pharmaceuticals (SHSE:600488) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Here's Why We Think Tianjin Tianyao Pharmaceuticals (SHSE:600488) Might Deserve Your Attention Today

Oct 28
Here's Why We Think Tianjin Tianyao Pharmaceuticals (SHSE:600488) Might Deserve Your Attention Today

Tianjin Tianyao Pharmaceuticals' (SHSE:600488) Performance Is Even Better Than Its Earnings Suggest

Apr 04
Tianjin Tianyao Pharmaceuticals' (SHSE:600488) Performance Is Even Better Than Its Earnings Suggest

Revenue & Expenses Breakdown

How Tianjin Tianyao Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SHSE:600488 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 243,5171521,042169
30 Jun 243,5611361,121157
31 Mar 243,6561081,223150
31 Dec 233,7831171,337158
30 Sep 233,8151361,360165
30 Jun 233,910981,435154
31 Mar 233,790801,410153
31 Dec 223,689351,394139
30 Sep 223,808471,426119
30 Jun 223,849631,408128
31 Mar 223,792461,364128
31 Dec 213,749491,385129
30 Sep 213,403-101,206142
30 Jun 213,201-11,161140
31 Mar 213,123191,089137
31 Dec 203,117341,054132
30 Sep 203,0051331,062141
30 Jun 203,0921431,057140
31 Mar 203,2971641,147140
31 Dec 193,3271621,094138
30 Sep 193,2501631,011124
30 Jun 192,981173918114
31 Mar 192,669157828104
31 Dec 182,42714580298
30 Sep 182,39814481289
30 Jun 182,278134678128
31 Mar 182,180134560108
31 Dec 171,97213040186
30 Sep 171,89410531466
30 Jun 171,8311053520
31 Mar 171,8411043740
31 Dec 161,689983270
30 Sep 161,558932640
30 Jun 161,527922280
31 Mar 161,326801340
31 Dec 151,405791360
30 Sep 151,415991240
30 Jun 151,403991220
31 Mar 151,386811180
31 Dec 141,389871140
30 Sep 141,374581260
30 Jun 141,366501180
31 Mar 141,398451140
31 Dec 131,481521180

Quality Earnings: 600488 has high quality earnings.

Growing Profit Margin: 600488's current net profit margins (4.3%) are higher than last year (3.6%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 600488's earnings have declined by 0.9% per year over the past 5 years.

Accelerating Growth: 600488's earnings growth over the past year (12.1%) exceeds its 5-year average (-0.9% per year).

Earnings vs Industry: 600488 earnings growth over the past year (12.1%) exceeded the Pharmaceuticals industry -2.5%.


Return on Equity

High ROE: 600488's Return on Equity (5.4%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 03:18
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Tianjin Tianyao Pharmaceuticals Co., Ltd. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null RESEARCH DEPARTMENTChina Merchants Securities Co. Ltd.
Jie YaoCitic Securities Co., Ltd.
null Research DepartmentGuotai Junan International Holdings Limited